Local and systemic thrombolytic therapy for acute venous thromboembolism

Clinics in Chest Medicine

Volumn 24, Issue 1, 2003, Pages 73-91

  Arcasoy, Selim M ^a,b   Vachani, Anil ^c  

^a Columbia Univ Coll of Phys/Surgs ^*  (United States)

^b Department of Obstetrics Gynecology   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; HEPARIN; RETEPLASE; STREPTOKINASE; UROKINASE;

ANTICOAGULATION; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; GASTROINTESTINAL HEMORRHAGE; HEART LEFT VENTRICLE FAILURE; HEMODYNAMICS; HIGH RISK PATIENT; HUMAN; HYPOXEMIA; LUNG EMBOLISM; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; RESPIRATORY FAILURE; RETROPERITONEAL HEMORRHAGE; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; VEIN THROMBOSIS;

EID: 0037346414     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(02)00051-5     Document Type: Review

References (126)

1. Coon WW, Willis PW. Deep venous thrombosis and pulmonary embolism: prediction, prevention and treatment. Am J Cardiol 1959;4:611-21.
2. Dalen JE, Alpert JS. Natural history of pulmonary embolism. Prog Cardiovasc Dis 1975;17:259-70.
3. Lilienfield DE, Chan E, Ehland J, Godbold JH, Landrigan PJ, Marsh G. Mortality from pulmonary embolism in the United States: 1962 to 1984. Chest 1990; 98:1067-72.
4. Morrell MT, Dunnill MS. The post-mortem incidence of pulmonary embolism in a hospital population. Br J Surg 1968;55:347-52.
5. Uhland H, Goldberg LM. Pulmonary embolism: a commonly missed clinical entity. Dis Chest 1964;45: 533-6.
6. Stein PD, Henry JW. Prevalence of acute pulmonary embolism among patients in a general hospital and at autopsy. Chest 1995;108:978-81.
7. Pineda LA, Hathwar VS, Grant BJ. Clinical suspicion of fatal pulmonary embolism. Chest 2001;120:791-5.
8. Wood KE. Major pulmonary embolism: review of a pathophysiologic approach to the golden hour of hemodynamically significant pulmonary embolism. Chest 2002;121:877-905.
9. Goldhaber SZ, Hennekens CH, Evans DA, Newton EC, Godleski JJ. Factors associated with correct antemortem diagnosis of major pulmonary embolism. Am J Med 1982;73:822-6.
10. Huisman MV, Buller HR, ten Cate JW, van Royen EA, Vreeken J, Kersten MJ, et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989;95:498-502.
11. Moser KM, Fedullo PF, LitteJohn JK, Crawford R. Frequent asymptomatic pulmonary embolism in patients with deep venous thrombosis. JAMA 1994;271: 223-5.
12. Decousus H, Leizorovicz A, Parent F, Page Y, Tardy B, Girard P, et al. A clinical trial ofvena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis: Prevention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group. N Engl J Med 1998;338:409-15.
13. Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 1998;279:458-62.
14. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125: 1-7.
15. Ginsberg JS, Hirsh J, Julian J, Vander LaandeVries M, Magier D, MacKinnon B, et al. Prevention and treatment of postphlebitic syndrome: results of a 3-part study. Arch Intern Med 2001;161:2105-9.
16. Brandjes DP, Buller HR, Heijboer H, Huisman MV, de Rijk M, Jagt H, et al. Randomised trial of effect of compression stockings in patients with symptomatic proximal-vein thrombosis. Lancet 1997;349:759-62.
17. Bernardi E, Prandoni P. The post-thrombotic syndrome. Curr Opin Pulm Med 2000;6:335-42.
18. Urokinase Pulmonary Embolism Trial. Phase 1 results: a cooperative study. JAMA 1970;214:2163-72.
19. Paraskos JA, Adelstein SJ, Smith RE, Rickman FD, Grossman W, Dexter L, et al. Late prognosis of acute pulmonary embolism. N Engl J Med 1973;289:55-8.
20. Dalen JE, Banas JS, Brooks HL, Evans GL, Paraskos JA, Dexter L. Resolution rate of acute pulmonary embolism in man. N Engl J Med 1969;280:1194-9.
21. Fred HL, Axelrad MA, Lewis JM, Alexander JK. Rapid resolution of pulmonary thromboemboli in man: angiographic study. JAMA 1966;196:1137-9.
22. Tow DE, Wagner NHJ. Recovery of pulmonary arterial blood flow in patients with pulmonary embolism. N Engl J Med 1967;276:1053-9.
23. Prandoni P, Cogo A, Bernardi E, Villalta S, Polistena P, Simioni P, et al. A simple ultrasound approach for detection of recurrent proximal-vein thrombosis. Circulation 1993;88:1730-5.
24. Heijboer H, Jongbloets LM, Buller HR, Lensing AW, ten Cate JW. Clinical utility of real-time compression ultrasonography for diagnostic management of patients with recurrent venous thrombosis. Acta Radiol 1992;33:297-300.
25. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest 1999;115:1695-707.
26. Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176S-93S.
27. Sharma GVRK, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980;303:842-5.
28. Sharma GV, Folland ED, McIntyre KM, Sasahara AA. Long-term benefit of thrombolytic therapy in patients with pulmonary embolism. Vasc Med 2000;5:91-5.
29. Tibbutt DA, Davies JA, Anderson JA, Fletcher EWL, Hamill J, Holt JM, et al. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. BMJ 1974; 1:343-7.
30. Ly B, Arnesen H, Erie H, Hol R. A controlled trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978;203: 465-70.
31. Marini C, Di Ricco G, Rossi G, Rindi M, Palla R, Giuntini C. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988;54:162-73.
32. A collaborative study by the PIOPED investigators: Tissue plasminogen activator for the treatment of acute pulmonary embolism. Chest 1990;97:528-33.
33. Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990;98:1473-9.
34. Dalla-Volta S, Palla A, Santolicandro A, Giuntini C, Pengo V, Visioli O, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen Activator Italian Multicenter Study 2. J Am Coll Cardiol 1992; 20:520-6.
35. Goldhaber SZ, Haire WD, Feldstein ML, Miller M, Toltzis R, Smith JL, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993;341:507-11.
36. Jerjes-Sanchez C, Ramirez-Rivera A, Garcia MDL, Arriaga-Nava R, Valencia S, Rosado-Buzzo A, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis 1995;2:227-9.
37. Urokinase-Streptokinase Embolism Trial. Phase 2 results: a cooperative study. JAMA 1974;229:1606-13.
38. The PIOPED Investigators. Value of the ventilation/perfusion scan in acute pulmonary embolism: results of the Prospective Investigation of Pulmonary Embolism Diagnosis (PIOPED). JAMA 1990;263:2753-9.
39. Alpert JS, Smith R, Carlson J, Ockene IS, Dexter L, Dalen JE. Mortality in patients treated for pulmonary embolism. JAMA 1976;236:1477-80.
40. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999;353:1386-9.
41. Ferrari E, Imbert A, Chevalier T, Mihoubi A, Morand P, Baudouy M. The ECG in pulmonary embolism: predictive value of negative T waves in precordial leads-80 case reports. Chest 1997;111:537-43.
42. Meyer T, Binder L, Hruska N, Luthe H, Buchwald AB. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol 2000;36:1632-6.
43. Giannitsis E, Muller-Bardorff M, Kurowski V, Weidtmann B, Wiegand U, Kampmann M, et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000;102:211-7.
44. Konstantinides S, Geibel A, Kasper W, Olschewski M, Blumel L, Just H. Patent foramen ovale is an important predictor of adverse outcome in patients with major pulmonary embolism. Circulation 1998; 97:1946-51.
45. Goldhaber SZ. Unsolved issues in the treatment of pulmonary embolism. Thromb Res 2001;103:V245-55.
46. Cannon CP, Goldhaber SZ. Cardiovascular risk stratification of pulmonary embolism. Am J Cardiol 1996; 78:1149-51.
47. Grifoni S, Olivotto I, Cecchini P, Pieralli F, Camaiti A, Santoro G, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000;101:2817-22.
48. Wolfe MW, Lee RT, Feldstein ML, Parker JA, Come PC, Goldhaber SZ. Prognostic significance of right ventricular hypokinesis and perfusion lung scan defects in pulmonary embolism. Am Heart J 1994;127: 1371-5.
49. Ribeiro A, Lindmarker P, Juhlin-Dannfelt A, Johnsson H, Jorfeldt L. Echocardiography Doppler in pulmonary embolism: right ventricular dysfunction as a predictor of mortality rate. Am Heart J 1997;134: 479-87.
50. Konstantinides S, Geibel A, Olschewski M, Heinrich F, Grosser K, Rauber K, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation 1997;96:882-8.
51. Goldhaber SZ. Pulmonary embolism thrombolysis: broadening the paradigm for its administration. Circulation 1997;96:716-8.
52. Come PC, Kim D, Parker JA, Goldhaber SZ, Braunwald E, Markis JE. Early reversal of right ventricular dysfunction in patients with acute pulmonary embolism after treatment with intravenous tissue plasminogen activator. J Am Coll Cardiol 1987;10:971-8.
53. Konstantinides S, Tiede N, Geibel A, Olschewski M, Just H, Kasper W. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol 1998;82:966-70.
54. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997;337:663-9.
55. Hamel E, Pacouret G, Vincentelli D, Forissier JF, Peycher P, Pottier JM, et al. Thrombolysis or heparin therapy in massive pulmonary embolism with right ventricular dilation: results from a 128-patient monocenter registry. Chest 2001;120:120-5.
56. Goldhaber SZ, Kessler CM, Heit J, Markis J, Sharma GVRK, Dawley D, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet 1988;2:293-8.
57. Meyer G, Sors H, Charbonnier B, Kasper W, Bassand J-P, Kerr IH, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. J Am Coll Cardiol 1992;19: 239-45.
58. Goldhaber SZ, Kessler CM, Heit JA, Elliot CG, Friedenberg WR, Heiselman DE, et al. Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol 1992;20:24-30.
59. Meneveau N, Schiele F, Vuillemenot A, Valette B, Grollier G, Bernard Y, et al. Streptokinase vs alteplase in massive pulmonary embolism: a randomized trial assessing right heart haemodynamics and pulmonary vascular obstruction. Eur Heart J 1997;18:1141-8.
60. Meneveau N, Schiele F, Metz D, Valette B, Attali P, Vuillemenot A, et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 1998;31:1057-63.
61. Tebbe U, Graf A, Kamke W, Zahn R, Forycki F, Kratzsch G, et al. Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolism. Am Heart J 1999;138:39-44.
62. Fava M, Loyola S, Flores P, Huete I. Mechanical fragmentation and pharmacologic thrombolysis in massive pulmonary embolism. J Vasc Interv Radiol 1997;8:261-6.
63. Stock KW, Jacob AL, Schnabel KJ, Bongartz G, Steinbrich W. Massive pulmonary embolism treatment with thrombus fragmentation and local fibrinolysis with recombinant human-tissue plasminogen activator. Cardiovasc Interv Radiol 1997;20:364-8.
64. Tapson VF, Davidson CJ, Bauman R, Newman GE, O'Connor CM, Stack RS. Rapid thrombolysis of massive pulmonary emboli without systemic fibrinogenolysis: intraembolic infusion of thrombolytic therapy. Am Rev Respir Dis 1992;145:A719.
65. Sze DY, Carey MB, Razavi MK. Treatment of massive pulmonary embolus with catheter-directed tenecteplase. J Vasc Interv Radiol 2001;12:1456-7.
66. De Gregorio MA, Gimeno MJ, Mainar A, Herrera M, Tobio R, Alfonso R, et al. Mechanical and enzymatic thrombolysis for massive pulmonary embolism. J Vasc Interv Radiol 2002;13:163-9.
67. Verstraete M, Miller GAH, Bounameaux H, Charbonnier B, Colle JP, Lecorf G, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988;77:353-60.
68. Goldhaber SZ, Feldstein ML, Sors H. Two trials of reduced bolus alteplase in the treatment of pulmonary embolism: an overview. Chest 1994;106:725-6.
69. Goldhaber SZ, Agnelli G, Levine MN. Reduced dose bolus alteplase vs conventional alteplase infusion for pulmonary embolism thrombolysis: an international multicenter randomized trial. Chest 1994; 106:718-24.
70. Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus vs 2-h infusion of alteplase in acute massive pulmonary embolism: a randomized controlled multicenter trial. Chest 1994;106:712-7.
71. Daniels LB, Parker JA, Patel SR, Grodstein F, Goldhaber SZ. Relation of duration of symptoms with response to thrombolytic therapy in pulmonary embolism. Am J Cardiol 1997;80:184-8.
72. Mikkola KM, Patel SR, Parker JA, Grodstein F, Goldhaber SZ. Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis. Am Heart J 1997;134:69-72.
73. Kanter DS, Mikkola KM, Patel SR, Parker JA, Goldhaber SZ. Thrombolytic therapy for pulmonary embolism: frequency of intracranial hemorrhage and associated risk factors. Chest 1997;111:1241-5.
74. Goodman LR, Curtin JJ, Mewissen MW, Foley WD, Lipchik RJ, Crain MR, et al. Detection of pulmonary embolism in patients with unresolved clinical and scintigraphic diagnosis: helical CT versus angiography. AJR Am J Roentgenol 1995;164:1369-74.
75. Blum AG, Delfau F, Grignon B, Beurrier D, Chabot F, Claudon M, et al. Spiral-computed tomography versus pulmonary angiography in the diagnosis of acute massive pulmonary embolism. Am J Cardiol 1994;74:96-8.
76. Remy-Jardin M, Remy J, Deschildre F, Artaud D, Beregi JP, Hossein-Foucher C, et al. Diagnosis of pulmonary embolism with spiral CT: comparison with pulmonary angiography and scintigraphy. Radiology 1996;200:699-706.
77. Stein PD, Hull RD, Pineo GF. The role of newer diagnostic techniques in the diagnosis of pulmonary embolism. Curr Opin Pulm Med 1999;5:212-5.
78. Goldhaber SZ. Echocardiography in the management of pulmonary embolism. Ann Intern Med 2002;136: 691-700.
79. Torbicki A, Kurzyna M, Ciurzynski M, Pruszczyk P, Pacho R, Kuch-Wocial A, et al. Proximal pulmonary emboli modify right ventricular ejection pattern. Eur Respir J 1999;13:616-21.
80. McConnell MV, Solomon SD, Rayan ME, Come PC, Goldhaber SZ, Lee RT. Regional right ventricular dysfunction detected by echocardiography in acute pulmonary embolism. Am J Cardiol 1996;78:469-73.
81. Pruszczyk P, Torbicki A, Pacho R, Chlebus M, Kuch-Wocial A, Pruszynski B, et al. Noninvasive diagnosis of suspected severe pulmonary embolism: transesophageal echocardiography vs spiral CT. Chest 1997;112:722-8.
82. Steiner P, Lund GK, Debatin JF, Steiner D, Nienaber C, Nicolas V, et al. Acute pulmonary embolism: value of transthoracic and transesophageal echocardiography in comparison with helical CT. AJR Am J Roentgenol 1996;167:931-6.
83. Molina JE, Hunter DW, Yedlicka JW, Cerra FB. Thrombolytic therapy for postoperative pulmonary embolism. Am J Surg 1992;163:375-80.
84. Severi P, Lo Pinto G, Poggio R, Andrioli G. Urokinase thrombolytic therapy of pulmonary embolism in neurosurgically treated patients. Surg Neurol 1994; 42:469-70.
85. Ahearn GS, Hadjiliadis D, Govert JA, Tapson VF. Massive pulmonary embolism during pregnancy successfully treated with recombinant tissue plasminogen activator: a case report and review of treatment options. Arch Intern Med 2002;162:1221-7.
86. Goldhaber SZ. Contemporary pulmonary embolism thrombolysis. Chest 1995;107:45S-51S.
87. Goldhaber SZ. Thrombolytic therapy in venous thromboembolism: clinical trials and current indications. Clin Chest Med 1995;16:307-20.
88. Rose PS, Punjabi NM, Pearse DB. Treatment of right heart thromboemboli. Chest 2002;121:806-14.
89. Greco F, Bisignani G, Serafini O, Guzzo D, Stingone A, Plastina F. Successful treatment of right heart thromboemboli with IV recombinant tissue-type plasminogen activator during continuous echocardiographic monitoring: a case series report. Chest 1999; 116:78-82.
90. Chakko S, Richards 3rd F. Right-sided cardiac thrombi and pulmonary embolism. Am J Cardiol 1987;59: 195-6.
91. Diebold J, Lohrs U. Venous thrombosis and pulmonary embolism: a study of 5039 autopsies. Pathol Res Pract 1991;187:260-6.
92. Lindblad B, Sternby NH, Bergqvist D. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ 1991;302:709-11.
93. Casazza F, Bongarzoni A, Centonze F, Morpurgo M. Prevalence and prognostic significance of right-sided cardiac mobile thrombi in acute massive pulmonary embolism. Am J Cardiol 1997;79:1433-5.
94. Pandey AS, Rakowski H, Mickleborough LL, Butany JW, Omran A, Parker TG. Right heart pulmonary embolism in transit: a review of therapeutic considerations. Can J Cardiol 1997;13:397-402.
95. Chartier L, Bera J, Delomez M, Asseman P, Beregi JP, Bauchart JJ, et al. Free-floating thrombi in the right heart: diagnosis, management, and prognostic indexes in 38 consecutive patients. Circulation 1999;99:2779-83.
96. Kinney EL, Wright RJ. Efficacy of treatment of patients with echocardiographically detected right-sided heart thrombi: a meta-analysis. Am Heart J 1989;118: 569-73.
97. Farfel Z, Shechter M, Vered Z, Rath S, Goof D, Gafni J. Review of echocardiographically diagnosed right heart entrapment of pulmonary emboli-in-transit with emphasis on management. Am Heart J 1987;113:171-8.
98. Chapoutot L, Nazeyrollas P, Metz D, Maes D, Maillier B, Jennesseaux C, et al. Floating right heart thrombi and pulmonary embolism: diagnosis, outcome and therapeutic management. Cardiology 1996;87: 169-74.
99. Bottiger BW, Bode C, Kern S, Gries A, Gust R, Glatzer R, et al. Efficacy and safety of thrombolytic therapy after initially unsuccessful cardiopulmonary resuscitation: a prospective clinical trial. Lancet 2001;357:1583-5.
100. Bottiger BW, Reim SM, Diezel G, Bohrer H, Martin E. High-dose bolus injection of urokinase: use during cardiopulmonary resuscitation for massive pulmonary embolism. Chest 1994;106:1281-3.
101. Bottiger BW, Bohrer H, Bach A, Motsch J, Martin E. Bolus injection of thrombolytic agents during cardiopulmonary resuscitation for massive pulmonary embolism. Resuscitation 1994;28:45-54.
102. Langdon RW, Swicegood WR, Schwartz DA. Thrombolytic therapy of massive pulmonary embolism during prolonged cardiac arrest using recombinant tissue-type plasminogen activator. Ann Emerg Med 1989;18:678-80.
103. Kurkciyan I, Meron G, Sterz F, Janata K, Domanovits H, Holzer M, et al. Pulmonary embolism as a cause of cardiac arrest: presentation and outcome. Arch Intern Med 2000;160:1529-35.
104. Abu-Laban RB, Christenson JM, Innes GD, van Beek CA, Wanger KP, McKnight RD, et al. Tissue plasminogen activator in cardiac arrest with pulseless electrical activity. N Engl J Med 2002;346:1522-8.
105. Robertson BR, Nilsson IM, Nylander G. Value of streptokinase and heparin in treatment of acute deep venous thrombosis: a coded investigation. Acta Chir Scand 1968;134:203-8.
106. Kakkar VV, Flanc C, Howe CT, O'Shea M, Flute PT. Treatment of deep vein thrombosis: a trial of heparin, streptokinase, and arvin. BMJ 1969;1:806-10.
107. Robertson BR, Nilsson IM, Nylander G. Thrombolytic effect of streptokinase as evaluated by phlebography of deep venous thrombi of the leg. Acta Chir Scand 1970;136:173-80.
108. Tsapogas MJ, Peabody RA, Wu KT, Karmody AM, Devaraj KT, Eckert C. Controlled study of thrombolytic therapy in deep vein thrombosis. Surgery 1973;74:973-84.
109. Porter JM, Seaman AJ, Common HH, Rosch J, Eidemiller LR, Calhoun AD. Comparison of heparin and streptokinase in the treatment of venous thrombosis. Am Surg 1975;41:511-9.
110. Arnesen H, Heilo A, Jakobsen E, Ly B, Skaga E. A prospective study of streptokinase and heparin in the treatment of deep vein thrombosis. Acta Med Scand 1978;203:457-63.
111. Elliot MS, Immelman EJ, Jeffery P, Benatar SR, Funston MR, Smith JA, et al. A comparative randomized trial of heparin versus streptokinase in the treatment of acute proximal venous thrombosis: an interim report of a prospective trial. Br J Surg 1979;66:838-43.
112. Schulman S, Granqvist S, Juhlin-Dannfelt A, Lockner D. Long-term sequelae of calf vein thrombosis treated with heparin or low-dose streptokinase. Acta Med Scand 1986;219:349-57.
113. Turpie AG, Levine MN, Hirsh J, Ginsberg JS, Cruickshank M, Jay R, et al. Tissue plasminogen activator (rt-PA) vs heparin in deep vein thrombosis: results of a randomized trial. Chest 1990;97:172S-5S.
114. Goldhaber SZ, Meyerovitz MF, Green D, Vogelzang RL, Citrin P, Heit J, et al. Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 1990;88:235-40.
115. Schweizer J, Kirch W, Koch R, Elix H, Hellner G, Forkmann L, et al. Short- and long-term results after thrombolytic treatment of deep venous thrombosis. J Am Coll Cardiol 2000;36:1336-43.
116. Kakkar VV, Howe CT, Laws JW, Flanc C. Late results of treatment of deep vein thrombosis. BMJ 1969;1: 810-1.
117. Bieger R, Boekhout-Mussert RJ, Hohmann F, Loeliger EA. Is streptokinase useful in the treatment of deep vein thrombosis? Acta Med Scand 1976;199: 81-8.
118. Common HH, Seaman AJ, Rosch J, Porter JM, Dotter CT. Deep vein thrombosis treated with streptokinase or heparin: follow-up of a randomized study. Angiology 1976;27:645-54.
119. Johansson L, Nylander G, Hedner U, Nilsson IM. Comparison of streptokinase with heparin: late results in the treatment of deep venous thrombosis. Acta Med Scand 1979;206:93-8.
120. Arnesen H, Hoiseth A, Ly B. Streptokinase or heparin in the treatment of deep vein thrombosis: follow-up results of a prospective study. Acta Med Scand 1982; 211:65-8.
121. Schweizer J, Elix H, Altmann E, Hellner G, Forkmann L. Comparative results of thrombolysis treatment with rt-PA and urokinase: a pilot study, Vasa 1998;27:167-71.
122. Schwieder G, Grimm W, Siemens HJ, Flor B, Hilden A, Gmelin E, et al. Intermittent regional therapy with rt-PA is not superior to systemic thrombolysis in deep vein thrombosis (DVT)-a German multicenter trial. Thromb Haemost 1995;74:1240-3.
123. Mewissen MW, Seabrook GR, Meissner MH, Cynamon J, Labropoulos N, Haughton SH. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology 1999;211:39-49.
124. Schulman S, Lockner D, Granqvist S, Bratt G, Paul C, Nyman D. A comparative randomized trial of low-dose versus high-dose streptokinase in deep vein thrombosis of the thigh. Thromb Haemost 1984;51: 261-5.
125. Heinrich F, Heinrich U. North Baden venous lysis trial (NBVL): multicentre prospective randomized phlebographically controlled trial on the effect of ultra-high versus conventional doses of streptokinase in fresh leg-pelvis venous thromboses. Vasc Med 1998; 3:87-94.
126. Bounameaux H, Banga JD, Bluhmki E, Coccheri S, Fiessinger JN, Haarmann W, et al. Double-blind, randomized comparison of systemic continuous infusion of 0.25 versus 0.50 mg/kg/24 of alteplase over 3 to 7 days for treatment of deep venous thrombosis in heparinized patients: results of the European Thrombolysis with rt-PA in Venous Thrombosis (ETTT) trial. Thromb Haemost 1992;67:306-9.